Biosimilars Present New Opportunities for Insurers to Manage Cost
Posted by Marie-Hélène Dugal on November 27, 2018
"Managing biosimilar drugs is a major challenge for insurers, said Marie-Hélène Dugal, Product Portfolio Manager, Drug Insurance Management Solutions for Medavie Blue Cross, during its annual seminar.
Learn more about the various approaches to consider to cover these drugs while ensuring plan sustainability. "It's all a matter of balancing access to care and the sustainability of plans."
Read the full article here (In French Only)
Marie-Hélène Dugal has been with Medavie Blue Cross for 15 years. Over the course of her career, she has developed expertise in dental and health claims, benefits management and system coding by working in various departments. Four years ago, Marie-Hélène joined the Drug Management Solutions department, where she first served...
2022 Benefits Canada Healthcare Survey
Posted by Medavie Blue Cross on Sep 27, 2022